| Keywords: |
adult; cancer survival; treatment outcome; aged; middle aged; survival analysis; clinical trial; cancer recurrence; doxorubicin; fluorouracil; dose response; drug efficacy; drug safety; risk benefit analysis; paclitaxel; cancer adjuvant therapy; cancer radiotherapy; chemotherapy, adjuvant; methotrexate; drug megadose; follow up; lymph node metastasis; neoplasm staging; cancer grading; medical decision making; gene overexpression; carboplatin; breast cancer; mastectomy; tumor volume; heart disease; antineoplastic combined chemotherapy protocols; ovariectomy; drug administration schedule; epidermal growth factor receptor 2; aromatase inhibitor; cancer screening; cyclophosphamide; dose-response relationship, drug; breast neoplasms; cancer mortality; thiotepa; risk assessment; docetaxel; cancer hormone therapy; randomized controlled trials; systematic review; folinic acid; tamoxifen; cancer relapse; epirubicin; maximum tolerated dose; antineoplastic agents, hormonal; estrogen receptor; progesterone receptor; trastuzumab; peripheral blood stem cell transplantation; aromatase inhibitors; breast surgery; meta analysis; cooperation; individualization; autologous bone marrow transplantation; selective estrogen receptor modulator; estrogen antagonists; humans; prognosis; human; female; priority journal; article
|
